Aditxt, Inc. (NASDAQ: ADTX)

Sector: Healthcare Industry: Biotechnology CIK: 0001726711
Market Cap 26,727.76
P/B 0.00
P/E 0.00
P/S 4.50
ROIC (Qtr) -250.88
Div Yield % 0.00
Rev 1y % (Qtr) -89.09
Total Debt (Qtr) 5.67 Mn
Debt/Equity (Qtr) -0.73
Add ratio to table...

About

Aditxt, Inc. (ADTX) is a biotech innovation company operating in the healthcare industry. The company focuses on developing and commercializing technologies that monitor and modulate the immune system, with the ultimate goal of prolonging life and enhancing its quality. Aditxt's immune reprogramming technologies are currently in the pre-clinical stage and are designed to retrain the immune system to induce tolerance, addressing rejection of transplanted organs, autoimmune diseases, and allergies. Aditxt generates revenue through the sale of its...

Read more

Investment thesis

Bull case

  • Operating cash flow of (22.59M) provides exceptional 26.15x coverage of minority interest expenses (863814), showing strong core operations.
  • Strong free cash flow of (22.59M) provides 8.24x coverage of acquisition spending (2.74M), indicating disciplined M&A strategy.
  • Retained earnings of (205.11M) represent substantial 26.52x of equity (7.73M), indicating strong internal capital generation.
  • Cash reserves of 407739 provide solid 1772.78x coverage of other non-current liabilities 230, indicating strong liquidity.
  • Cash reserves of 407739 exceed inventory value of 6572 by 62.04x, indicating strong liquidity and inventory management.

Bear case

  • Investment activities of (5.17M) provide weak support for R&D spending of 3.34M, which is -1.55x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Cash reserves of 407739 provide limited coverage of acquisition spending of (2.74M), which is -0.15x, suggesting aggressive expansion might strain liquidity if market conditions deteriorate.
  • The company's operating cash flow of (22.59M) shows concerning coverage of stock compensation expenses of 477680, with a -47.29 ratio indicating potential earnings quality issues.
  • Operating earnings of (41.82M) show weak coverage of depreciation charges of 371332, with a -112.62 ratio indicating high capital intensity and potential reinvestment needs.
  • High receivables of 39182 relative to inventory of 6572 (5.96 ratio) suggests aggressive credit terms or collection difficulties, potentially masking revenue quality issues.

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,204.25 Bn -1,306.67 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 486.51 Bn 7,097.20 97.84 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 122.05 Bn 30.87 10.17 1.85 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 83.00 Bn 18.42 5.79 2.71 Bn
5 ARGX Argenx Se 50.78 Bn 33.71 26,480.10 -
6 ALNY Alnylam Pharmaceuticals, Inc. 43.66 Bn 139.17 11.76 2.97 Bn
7 BNTC Benitec Biopharma Inc. 43.61 Bn -941.82 0.00 0.00 Bn
8 INSM INSMED Inc 28.88 Bn -24.40 64.61 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 0.42 11.06
EV to Cash from Ops. EV/CFO -0.22 26.32
EV to Debt EV to Debt 0.88 762.61
EV to EBIT EV/EBIT -0.12 -13.49
EV to EBITDA EV/EBITDA -0.25 8.61
EV to Free Cash Flow [EV/FCF] EV/FCF -0.22 25.66
EV to Market Cap EV to Market Cap 185.93 203.37
EV to Revenue EV/Rev 835.92 156.31
Price to Book Value [P/B] P/B 0.00 20.59
Price to Earnings [P/E] P/E 0.00 -0.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Div Coverage (Qtr) 0.00 -12.64
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.14
Interest Coverage Int. cover (Qtr) -99.72 956.66
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 0.00 7.87
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) -5.32 753.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) -3.79 -57.63
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 31.47 8.83
EBIT Growth (1y) % EBIT 1y % (Qtr) -3.79 -67.21
EBT Growth (1y) % EBT 1y % (Qtr) 8.67 -23.74
EPS Growth (1y) % EPS 1y % (Qtr) -89.56 -7.02
FCF Growth (1y) % FCF 1y % (Qtr) -55.24 -40.48
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 86.75 264.51
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.00 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 0.02 3.92
Current Ratio Curr Ratio (Qtr) 0.02 7.33
Debt to Equity Ratio Debt/Equity (Qtr) -0.73 0.48
Interest Cover Ratio Int Coverage (Qtr) -99.72 956.66
Times Interest Earned Times Interest Earned (Qtr) -99.72 956.66
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -697,198.40 -17,888.70
EBIT Margin % EBIT Margin % (Qtr) -703,444.47 -18,246.34
EBT Margin % EBT Margin % (Qtr) -710,498.74 -19,108.08
Gross Margin % Gross Margin % (Qtr) -1,111.20 -10.30
Net Profit Margin % Net Margin % (Qtr) -710,498.70 -19,056.96